One mission of the CIS Advocacy Committee is to facilitate medically necessary diagnostic testing and treatments by providing clinicians access to template letters. In an effort to assist with coverage from insurance companies, designated template letters are available for download and editing below. Further advocacy letters are available for members in the Members Only section of the CIS website here.
Genetic Testing
IVIG Initiation
SCIG Initiation
Disclaimer: These template letters (IVIG, SCIG, and Genetic Testing) available through CIS should only serve as a guideline for therapy, and CIS is not responsible for any financial burden or adverse outcomes that may arise by use of the templates.
With the recent decision by some commercial health insurers to discontinue coverage for subcutaneous immunoglobulin (SCIG) therapy and require patients to transition to a covered intravenous immunoglobulin (IVIG), the CIS Advocacy Committee has put together the statement below. The CIS Advocacy Committee and CIS Executive Council stand. in strong support of the autonomy of the physician-patient relationship to allow individualized decisions to be made on the optimal delivery route of immunoglobulin therapy to patients with primary immunodeficiency (PI).
Letter
The Advocacy Committee meets on an as-needed basis to develop the extent and the manner in which CIS pursues actions to influence government policy at the state and federal level.
Their activities over the past years include the following: